Ajanta Pharma 将来の成長
Future 基準チェック /36
Ajanta Pharma利益と収益がそれぞれ年間16.3%と11.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に23.7% 16.3%なると予測されています。
主要情報
16.3%
収益成長率
16.3%
EPS成長率
| Pharmaceuticals 収益成長 | 18.3% |
| 収益成長率 | 11.2% |
| 将来の株主資本利益率 | 23.7% |
| アナリストカバレッジ | Good |
| 最終更新日 | 29 Oct 2024 |
今後の成長に関する最新情報
Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Oct 31
Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 04Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results
May 05Recent updates
Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Oct 31Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Sep 10We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Aug 23Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 04Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E
Aug 01With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Jun 01Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results
May 05Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price
Apr 05We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Feb 23Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected
Dec 23Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Aug 26These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well
Feb 07Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Oct 24Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Aug 25Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?
Jul 19A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Apr 28Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Mar 14I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut
Feb 06Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Dec 13Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50
Oct 31Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching
Sep 22Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?
Sep 08Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?
Aug 26Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet
Jul 07Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?
Jun 14Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?
May 15Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 10Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Mar 11Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?
Feb 24The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On
Jan 30
What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?
Jan 18Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Jan 06業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 3/31/2027 | 59,429 | 13,179 | 10,903 | 11,809 | 7 |
| 3/31/2026 | 52,773 | 11,131 | 8,563 | 9,720 | 11 |
| 3/31/2025 | 47,273 | 9,584 | 7,822 | 9,381 | 8 |
| 9/30/2024 | 44,908 | 8,750 | 9,127 | 11,625 | N/A |
| 6/30/2024 | 43,326 | 8,538 | N/A | N/A | N/A |
| 3/31/2024 | 42,087 | 8,162 | 6,327 | 7,851 | N/A |
| 12/31/2023 | 40,365 | 7,357 | N/A | N/A | N/A |
| 9/30/2023 | 39,031 | 6,602 | 6,610 | 8,199 | N/A |
| 6/30/2023 | 38,128 | 6,215 | N/A | N/A | N/A |
| 3/31/2023 | 37,426 | 5,880 | 6,176 | 7,921 | N/A |
| 12/31/2022 | 37,311 | 6,169 | N/A | N/A | N/A |
| 9/30/2022 | 35,972 | 6,742 | 5,027 | 6,613 | N/A |
| 6/30/2022 | 35,439 | 7,136 | N/A | N/A | N/A |
| 3/31/2022 | 33,410 | 7,127 | 4,129 | 5,617 | N/A |
| 12/31/2021 | 32,275 | 7,207 | N/A | N/A | N/A |
| 9/30/2021 | 31,384 | 7,056 | 3,607 | 5,379 | N/A |
| 6/30/2021 | 29,695 | 6,799 | N/A | N/A | N/A |
| 3/31/2021 | 28,897 | 6,539 | 4,047 | 5,763 | N/A |
| 12/31/2020 | 28,148 | 6,238 | N/A | N/A | N/A |
| 9/30/2020 | 27,173 | 5,547 | 3,593 | 5,334 | N/A |
| 6/30/2020 | 26,441 | 5,008 | N/A | N/A | N/A |
| 3/31/2020 | 25,879 | 4,677 | 2,174 | 4,568 | N/A |
| 12/31/2019 | 24,211 | 4,274 | N/A | N/A | N/A |
| 9/30/2019 | 22,550 | 3,868 | 1,451 | 4,409 | N/A |
| 6/30/2019 | 21,563 | 3,958 | N/A | N/A | N/A |
| 3/31/2019 | 20,554 | 3,870 | 315 | 3,745 | N/A |
| 12/31/2018 | 20,654 | 3,926 | N/A | N/A | N/A |
| 9/30/2018 | 21,674 | 4,731 | N/A | N/A | N/A |
| 6/30/2018 | 21,636 | 4,796 | N/A | N/A | N/A |
| 3/31/2018 | 21,258 | 4,686 | N/A | 2,811 | N/A |
| 12/31/2017 | 20,590 | 4,882 | N/A | N/A | N/A |
| 9/30/2017 | 20,050 | 4,833 | N/A | N/A | N/A |
| 6/30/2017 | 19,805 | 4,821 | N/A | N/A | N/A |
| 3/31/2017 | 19,833 | 5,068 | N/A | 6,093 | N/A |
| 12/31/2016 | 19,386 | 4,908 | N/A | N/A | N/A |
| 9/30/2016 | 18,821 | 4,622 | N/A | N/A | N/A |
| 6/30/2016 | 18,072 | 4,350 | N/A | N/A | N/A |
| 3/31/2016 | 17,340 | 4,156 | N/A | 3,261 | N/A |
| 12/31/2015 | 16,809 | 3,692 | N/A | N/A | N/A |
| 9/30/2015 | 16,160 | 3,510 | N/A | N/A | N/A |
| 6/30/2015 | 15,502 | 3,340 | N/A | N/A | N/A |
| 3/31/2015 | 14,736 | 3,099 | N/A | 2,794 | N/A |
| 3/31/2014 | 12,083 | 2,339 | N/A | 2,124 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: AJANTPHARMの予測収益成長率 (年間16.3% ) は 貯蓄率 ( 6.7% ) を上回っています。
収益対市場: AJANTPHARMの収益 ( 16.3% ) Indian市場 ( 18.1% ) よりも低い成長が予測されています。
高成長収益: AJANTPHARMの収益は増加すると予測されていますが、大幅には増加しません。
収益対市場: AJANTPHARMの収益 ( 11.2% ) Indian市場 ( 10.2% ) よりも速いペースで成長すると予測されています。
高い収益成長: AJANTPHARMの収益 ( 11.2% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: AJANTPHARMの 自己資本利益率 は、3年後には高くなると予測されています ( 23.7 %)